Sapropterin Dihydrochloride (Kuvan)
Small molecule
Evidence outlook
Approved: Phenylketonuria
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (1)
- Kuvan is indicated for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with phenylketonuria (PKU) who have been shown to be responsive to such treatment. Kuvan is also indicated for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with tetrahydrobiopterin (BH4) deficiency who have been shown to be responsive to such treatment.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00104247 NCT00104247 · Phenylketonuria The trial randomized 89 participants to double-blind sapropterin or placebo, with 41 and 46 participants included in the primary analysis. Its primary endpoint, change in blood phenylalanine—a disease-defining physiological measure for phenylketonuria—was significantly better with sapropterin than placebo (p<0.001), supporting strong evidence from this study. Registry: NCT00104247 | 3 | Change in Blood Phenylalanine Levels From Baseline to Week 6. | Change in Blood Phenylalanine Levels From Baseline to Week 6. (baseline to week 6): Sapropterin Dihydrochloride — Baseline Blood Phe Level: 843 micromole per liter (Standard Deviation 300); Week 6 Blood Phe Level: 607 micromole per liter (Standard Deviation 377); Mean Change in Blood Phe from Baseline to Week 6: -239 micromole per liter (Standard Deviation 38) | Placebo — Baseline Blood Phe Level: 888 micromole per liter (Standard Deviation 323); Week 6 Blood Phe Level: 891 micromole per liter (Standard Deviation 348); Mean Change in Blood Phe from Baseline to Week 6: 6 micromole per liter (Standard Deviation 36) | Reliable signal | link ↗ |
View 2 more trials
NCT00272792 NCT00272792 · Phenylketonuria Randomized, double-blind and placebo-controlled, and the primary measure (how much dietary phenylalanine children could tolerate while keeping blood levels controlled) clearly favoured sapropterin, with a difference of 17.7 mg/kg/day (P<.001) in the published report. The study is small (33 vs 12 children), and no power calculation or planned enrolment was found in the record or the published abstract. Registry: NCT00272792 | 3 | Amount of Dietary Supplemented Phenylalanine (Phe)Tolerated in Children With Phenylketonuria (at Week 10) | Phenylalanine supplement tolerated at week 10: sapropterin 20.9 (SD 15.4) vs placebo 2.9 (SD 4.0) mg/kg/day; mean difference 17.7 (SE 4.5) mg/kg/day, P<.001 (n=33 and 12) (Trefz et al., J Pediatr 2009). | Partial signal | link ↗ |
SPARK NCT01376908 · Phenylketonuria Randomized and controlled against diet alone, and the primary measure (dietary phenylalanine tolerance at week 26) was significantly higher with sapropterin (difference 30.5 mg/kg/day, p<0.001). The study was open-label with no placebo, and phenylalanine tolerance is a prescribed diet amount that unblinded investigators adjusted, so the result is less protected from bias. Registry: NCT01376908 | 3 | Dietary Phenylalanine (Phe) Tolerance at Week 26 2014-07 | Dietary phenylalanine tolerance at week 26: sapropterin plus Phe-restricted diet 80.6 vs diet alone 50.1 mg/kg/day; difference 30.5 mg/kg/day (95% CI 18.7 to 42.3), p<0.001 (SPARK, Orphanet J Rare Dis 2017). | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (3)
What this study did
What this study did
What this study did
Phase 2 (21)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Phase 1 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other Phenylalanine hydroxylase (PAH) drugs
Sepiapterin. Compare all 2 Phenylalanine hydroxylase (PAH) drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Phenylketonuria: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Sapropterin Dihydrochloride (Kuvan): this drug | Approved | Small molecule | Phenylalanine hydroxylase (PAH) | Reliable signal | NCT00104247: Change in Blood Phenylalanine Levels From Baseline to Week 6. (baseline to week 6): Sapropterin Dihydrochloride — Baseline Blood Phe Level: 843 micromole per liter (Standard Deviation 300); Week 6 Blood Phe Level: 607 micromole per liter (Standard Deviation 377); Mean Change in Blood Phe from Baseline to Week 6: -239 micromole per liter (Standard Deviation 38) | Placebo — Baseline Blood Phe Level: 888 micromole per liter (Standard Deviation 323); Week 6 Blood Phe Level: 891 micromole per liter (Standard Deviation 348); Mean Change in Blood Phe from Baseline to Week 6: 6 micromole per liter (Standard Deviation 36) NCT00272792: Phenylalanine supplement tolerated at week 10: sapropterin 20.9 (SD 15.4) vs placebo 2.9 (SD 4.0) mg/kg/day; mean difference 17.7 (SE 4.5) mg/kg/day, P<.001 (n=33 and 12) (Trefz et al., J Pediatr 2009). | |
| Pegvaliase (PALYNZIQ) | Approved | Protein / enzyme therapeutic | Phenylalanine ammonia lyase (enzyme substitution) | Weak signal | Featured results are safety only in this race | |
| Sepiapterin | Approved | Small molecule | Phenylalanine hydroxylase (PAH) | Reliable signal | No reviewed efficacy summary in this indication | |
| BEAM-304 | —(overall) | Gene therapy / editing | PAH gene (phenylalanine hydroxylase) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Sapropterin Dihydrochloride (Kuvan) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.